TP53 and acute myeloid leukemia: In acute myeloid leukemia (AML), TP53 mutations serve as predictors of resistance and recurrence, with mutations or loss closely linked to chemotherapy resistance, irrespective of age, karyotype, or other genetic markers [12–14].